- Global Pharma News & Resources

Adrenergic Antagonist - Pipeline Insight, 2019 -

The "Adrenergic Antagonist - Pipeline Insight, 2019" drug pipelines has been added to's offering.

Adrenergic Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adrenergic Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for Adrenergic Antagonist
  • Features the Adrenergic Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Adrenergic Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Adrenergic Antagonist

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Adrenergic Antagonist to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Adrenergic Antagonist research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for Adrenergic Antagonist
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Adrenergic Antagonist to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Topics Covered

1. Report Introduction

2. Adrenergic Antagonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Adrenergic Antagonist

4. Comparative Analysis

5. Adrenergic Antagonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Adrenergic Antagonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Aspen Park Pharmaceuticals
  • Astellas Pharma
  • GlaxoSmithKline
  • AstraZeneca
  • Otsuka Pharmaceutical
  • VUFB
  • Organon
  • sanofi-aventis
  • Roche
  • PsiOxus Therapeutics
  • Saniona
  • Roivant Sciences Ltd.
  • Ocularis Pharma
  • Beijing CoSci Med-Tech
  • Hanmi Pharmaceutical
  • Kissei Pharmaceutical

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 08-Feb-2019